CENTRAL NERVOUS SIDE-EFFECTS FOLLOWING IFOSFAMIDE MONOTHERAPY OF ADVANCED RENAL-CARCINOMA

[1] ALLEN LM, 1975, CLIN PHARMACOL THER, V17, P492

[2] CREAVEN PJ, 1974, CLIN PHARMACOL THER, V16, P77

[3] HARTWICH G, 1978, MED KLIN, V73, P1247

[4] Hoefer-Janker H, 1975, Med Welt, V26, P972

[5] RITTER S, 1977, MED WELT, V28, P1395

[6] SCHMOLL HJ, 1977, INT HOLOXAN S P DUSS, P121

[7] SCHNITKER J, 1976, ARZNEIMITTEL-FORSCH, V26, P1

[8] TALLEY RW, 1973, CANCER-AM CANCER SOC, V32, P1062, DOI 10.1002/1097-0142(197311)32:5<1062::AID-CNCR2820320506>3.0.CO

[9] 2-U

[10] TUCKER WG, 1977, INT HOLOXAN S P DUSS, P132

[1] ALLEN LM, 1975, CLIN PHARMACOL THER, V17, P492

[2] CREAVEN PJ, 1974, CLIN PHARMACOL THER, V16, P77

[3] HARTWICH G, 1978, MED KLIN, V73, P1247

[4] Hoefer-Janker H, 1975, Med Welt, V26, P972

[5] RITTER S, 1977, MED WELT, V28, P1395

[6] SCHMOLL HJ, 1977, INT HOLOXAN S P DUSS, P121

[7] SCHNITKER J, 1976, ARZNEIMITTEL-FORSCH, V26, P1

[8] TALLEY RW, 1973, CANCER-AM CANCER SOC, V32, P1062, DOI 10.1002/1097-0142(197311)32:5<1062::AID-CNCR2820320506>3.0.CO

[9] 2-U

[10] TUCKER WG, 1977, INT HOLOXAN S P DUSS, P132